Showing 4031-4040 of 8866 results for "".
- Study: Cryomodulation May Curb Acne Inflammationhttps://practicaldermatology.com/news/study-cryomodulation-may-curb-acne-inflammation/2462718/Cryomodulation was associated with significant inflammation reduction in patients with acne vulgaris, based on data from a new pilot study presented at the American Society for Laser Medicine and Surgery 43rd Annual Conference on Energy-based Medicine and Science in Baltimore.
- Tara L. Azzano Appointed Executive Director of ASDShttps://practicaldermatology.com/news/tara-l-azzano-appointed-executive-director-asds/2462658/The American Society for Dermatologic Surgery (ASDS), the largest organization in the U.S. dedicated solely to dermatologic surgeons, announced the appointment of Tara L. Azzano as Executive Director, according to a news release. Ms. Azzano brings with her over two decades of experience
- Analysis Highlights Factors Affecting Long-term Antibiotic Prescriptions for Acnehttps://practicaldermatology.com/news/analysis-highlights-factors-affecting-long-term-antibiotic-prescriptions-acne/2462633/A new analysis provided insight into the thinking of dermatologists prescribing antibiotics for treating acne. The research team set out to identify factors influencing prolonged oral antibiotic prescriptions for acne treatment by dermatologists, despite guidelines recommending limitation
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreementhttps://practicaldermatology.com/news/arca-biopharma-and-oruka-therapeutics-announce-merger-agreement/2462611/ARCA biopharma and Oruka Therapeutics, a privately held biotechnology company developing novel biologics designed to set a new standard for the treatm
- Meta-analysis: Omalizumab Alleviates Psychiatric Comorbidities of Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/meta-analysis-omalizumab-alleviates-psychiatric-comorbidities-chronic-spontaneous-urticaria/2462572/A new review suggests that omalizumab was associated with a reduction in psychiatric cormidities in a number of different studies and settings. The systematic review and meta-analysis sourght to assess the clinical impacts of omalizumab on depression, anxiety, and sleep disturbances in p
- Rosacea Awareness Month: Society Highlights Challenges of Disruptive Disorderhttps://practicaldermatology.com/news/rosacea-awareness-month-society-highlights-challenges-disruptive-disorder/2462552/April is designated as National Rosacea Awareness Month, and the National Rosacea Society (NRS) is taking steps to highlight the unique challenges that milli
- Study Validates Thermal Imaging, ALT-70 Model for Distinguishing Cellulitis from Pseudocellulitishttps://practicaldermatology.com/news/study-validates-thermal-imaging-alt-70-model-distinguishing-cellulitis-pseudocellulitis/2462541/A new diagnostic validation study in JAMA Dermatology has shed light on the potential of surface thermal imaging and the ALT-70 (asymmetry, leukocytosis, tachycardia, and age ≥70 years) prediction model in differentiating cellulitis from pseudocellulitis. "Cellulitis is misdiagno
- Deucravacitinib Improves Patient-Reported Outcomes for Psoriatic Arthritishttps://practicaldermatology.com/news/deucravacitinib-improves-patient-reported-outcomes-psoriatic-arthritis/2462540/Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a phase 2 trial. To assess the effects of deucravacitinib in this patient population, the study aut
- Study: Pembrolizumab Shows Efficacy in Japanese Patients with Advanced Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-shows-efficacy-japanese-patients-advanced-melanoma/2462539/A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study over a 12-month period. The study evaluated pembrolizumab's long-term efficacy and safety in individua
- Integrated Dermatology Appoints Tushar Ramani, MD, as CEOhttps://practicaldermatology.com/news/integrated-dermatology-appoints-tushar-ramani-md-ceo/2462493/Integrated Dermatology has announced the appointment of Tushar Ramani, MD, as the company's new chief executive officer (CEO). Dr. Ramani will be replacing Jeff Queen, who after two decades as CEO and executive chairman, is transitioning to the role of co-executive chairman of the Board alongside